ArticleBiomedical reports2026
Oxaliplatin-induced autoimmune-like hepatitis: A case report highlighting the role of clinical pharmacists.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study reported the case of a 48-year-old female who developed drug-induced autoimmune-like hepatitis (DI-ALH) during adjuvant oxaliplatin, 5-fluorouracil and leucovorin calcium (FOLFOX) therapy for rectal cancer. The initial liver injury was attributed to non-specific chemotherapy-associated hepatotoxicity, resulting in a delay in the correct diagnosis. Recurrent transaminitis following oxaliplatin rechallenge subsequently suggested an immune-mediated mechanism. A clinical pharmacist played a central role in the multidisciplinary team by leading the causality assessment and developing an individualized corticosteroid management strategy, which enabled completion of all 12 planned cycles of FOLFOX without severe hepatic flares. Liver enzyme levels normalized following completion of chemotherapy and remained stable after glucocorticoid discontinuation during 12 months of follow-up. The present case report highlighted that DI-ALH may closely resemble idiopathic autoimmune hepatitis but typically resolves after withdrawal without the need for long-term immunosuppressive therapy. It also underscored the important contribution of clinical pharmacists in the recognition, assessment and management of complex chemotherapy-associated toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.